Log in

Relevant bibliographies by topics / Oxyntomoduline / Journal articles

To see the other types of publications on this topic, follow the link: Oxyntomoduline.

Journal articles on the topic 'Oxyntomoduline'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Oxyntomoduline.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Uesaka, Toshihiro, Keiichi Yano, Seiji Sugimoto, and Masaaki Ando. "Glucagon-like peptide isolated from the eel intestine: effects on atrial beating." Journal of Experimental Biology 204, no. 17 (2001): 3019–26. http://dx.doi.org/10.1242/jeb.204.17.3019.

Full text

Abstract:

SUMMARYA new glucagon-like peptide was isolated from the intestine of the eel Anguilla japonica. The primary structure was determined by sequence analysis after cleavage with lysyl endopeptidase, quantitative amino acid analysis and fast atom bombardment mass spectrometry as HSQGTFTNDY10SKYLETRRAQ20DFVQWLMNSK30RSGGPT. Since its structure is similar to that of oxyntomodulins (OXMs) reported in various vertebrates, we named this peptide eel oxyntomodulin (eOXM). We found that eOXM enhanced the contractile force and the beating rate of the eel atrium in a dose-dependent manner. These effects of e

APA, Harvard, Vancouver, ISO, and other styles

2

Druce, Maralyn R., and Stephen R. Bloom. "Oxyntomodulin." Treatments in Endocrinology 5, no. 5 (2006): 265–72. http://dx.doi.org/10.2165/00024677-200605050-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Druce, Maralyn, and Mohammad Ghatei. "Oxyntomodulin." Current Opinion in Endocrinology & Diabetes 13, no. 1 (2006): 49–55. http://dx.doi.org/10.1097/01.med.0000200526.08653.bb.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Patterson, Michael, Kevin G. Murphy, Sejal R. Patel, et al. "Hypothalamic Injection of Oxyntomodulin Suppresses Circulating Ghrelin-Like Immunoreactivity." Endocrinology 150, no. 8 (2009): 3513–20. http://dx.doi.org/10.1210/en.2008-0796.

Full text

Abstract:

Ghrelin is a gastric peptide that regulates appetite and GH secretion. Circulating ghrelin levels are elevated by fasting and suppressed postprandially. However, the mechanisms regulating circulating ghrelin levels are unclear. Oxyntomodulin is an anorexic peptide hormone released from L cells in the gut. We investigated the effects of intracerebroventricular (icv) administration of oxyntomodulin on circulating ghrelin levels. The icv administration of 1, 3, or 10 nmol oxyntomodulin reduced circulating acylated and total (acylated and des-acylated) ghrelin 60 min after icv injection. Administr

APA, Harvard, Vancouver, ISO, and other styles

5

Stepanenko, V. N., R. S. Esipov, A. I. Gurevich, L. A. Chupova, and A. I. Miroshnikov. "Recombinant oxyntomodulin." Russian Journal of Bioorganic Chemistry 33, no. 2 (2007): 227–32. http://dx.doi.org/10.1134/s1068162007020045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bak, Monika J., Nicolai Wewer Albrechtsen, Jens Pedersen, et al. "Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans." European Journal of Endocrinology 170, no. 4 (2014): 529–38. http://dx.doi.org/10.1530/eje-13-0941.

Full text

Abstract:

AimTo determine the specificity and sensitivity of assays carried out using commercially available kits for glucagon and/or oxyntomodulin measurements.MethodsTen different assay kits used for the measurement of either glucagon or oxyntomodulin concentrations were obtained. Solutions of synthetic glucagon (proglucagon (PG) residues 33–61), oxyntomodulin (PG residues 33–69) and glicentin (PG residues 1–69) were prepared and peptide concentrations were verified by quantitative amino acid analysis and a processing-independent in-house RIA. Peptides were added to the matrix (assay buffer) supplied

APA, Harvard, Vancouver, ISO, and other styles

7

Pendharkar, Sayali, Ruma Singh, Aya Cervantes, Steve DeSouza, Sakina Bharmal, and Maxim Petrov. "Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis." Hormone and Metabolic Research 51, no. 03 (2018): 191–99. http://dx.doi.org/10.1055/a-0802-9569.

Full text

Abstract:

AbstractThe study was aimed to investigate gut hormone responses to mixed meal test in individuals with new-onset prediabetes or diabetes after acute pancreatitis (cases) compared with healthy controls, and the effect of body fat parameters. A total of 29 cases and 29 age- and sex-matched healthy controls were recruited. All participants were given standard mixed meal drink and blood samples were collected to measure dipeptidyl peptidase IV, gastric inhibitory peptide, glucagon like peptide-1, insulin, oxyntomodulin, and peptide YY. Body fat parameters were measured using magnetic resonance im

APA, Harvard, Vancouver, ISO, and other styles

8

Stanley, Sarah, Katie Wynne, and Steve Bloom. "Gastrointestinal Satiety Signals III. Glucagon-like peptide 1, oxyntomodulin, peptide YY, and pancreatic polypeptide." American Journal of Physiology-Gastrointestinal and Liver Physiology 286, no. 5 (2004): G693—G697. http://dx.doi.org/10.1152/ajpgi.00536.2003.

Full text

Abstract:

Many peptides are synthesized and released from the gastrointestinal tract and pancreas, including pancreatic polypeptide (PP) and the products of the gastrointestinal L cells, glucagon-like peptide 1 (GLP-1), oxyntomodulin, and peptide YY (PYY). Whereas their roles in regulation of gastrointestinal function have been known for some time, it is now evident that they also influence eating behavior. This review considers the anorectic peptides PYY, PP, GLP-1, and oxyntomodulin, which decrease appetite and promote satiety in both animal models and humans.

APA, Harvard, Vancouver, ISO, and other styles

9

Schjoldager, Birgit, Poul Erik Mortensen, John Myhre, John Christiansen, and Jens Juul Holst. "Oxyntomodulin from distal gut." Digestive Diseases and Sciences 34, no. 9 (1989): 1411–19. http://dx.doi.org/10.1007/bf01538078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lee, Anita Y. H., Derek L. Chappell, Monika J. Bak, et al. "Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test." Clinical Chemistry 62, no. 1 (2016): 227–35. http://dx.doi.org/10.1373/clinchem.2015.244251.

Full text

Abstract:

Abstract BACKGROUND Proglucagon-derived peptides (PGDPs), which include glucagon-like peptide (GLP)-1, glucagon, and oxyntomodulin, are key regulators of glucose homeostasis and satiety. These peptide hormones are typically measured with immuno-based assays (e.g., ELISA, RIA), which often suffer from issues of selectivity. METHODS We developed a multiplexed assay for measuring PGDPs including GLP-1 (7–36) amide, GLP-1 (9–36) amide, glucagon, and oxyntomodulin by mass spectrometry and used this assay to examine the effect of a meal tolerance test on circulating concentrations of these hormones.

APA, Harvard, Vancouver, ISO, and other styles

11

Nielsen, Mette S., Christian Ritz, Nicolai J. Wewer Albrechtsen, Jens Juul Holst, Carel W. le Roux, and Anders Sjödin. "Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss." Journal of Clinical Endocrinology & Metabolism 105, no. 4 (2020): e1064-e1074. http://dx.doi.org/10.1210/clinem/dgaa061.

Full text

Abstract:

Abstract Background Alterations in several gastrointestinal hormones are implicated in the postoperative suppression of food intake leading to weight loss after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). The aim was to evaluate changes in responses of gastrointestinal hormones after RYGB and SG and the associations of these changes with weight loss, energy intake, and food preferences. Methods Forty-two subjects with severe obesity were included (32 RYGB; 10 SG). Postprandial responses of glicentin, oxyntomodulin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and ghrelin

APA, Harvard, Vancouver, ISO, and other styles

12

Pocai, Alessandro. "Unraveling oxyntomodulin, GLP1's enigmatic brother." Journal of Endocrinology 215, no. 3 (2012): 335–46. http://dx.doi.org/10.1530/joe-12-0368.

Full text

Abstract:

Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the anti

APA, Harvard, Vancouver, ISO, and other styles

13

Pocai, Alessandro. "Action and therapeutic potential of oxyntomodulin." Molecular Metabolism 3, no. 3 (2014): 241–51. http://dx.doi.org/10.1016/j.molmet.2013.12.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Price, Samantha L., James S. Minnion, and Stephen R. Bloom. "Increased food intake with oxyntomodulin analogues." Peptides 73 (November 2015): 95–100. http://dx.doi.org/10.1016/j.peptides.2015.09.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Holst, Jens J., Nicolai J. Wewer Albrechtsen, Maria Buur Nordskov Gabe, and Mette Marie Rosenkilde. "Oxyntomodulin: Actions and role in diabetes." Peptides 100 (February 2018): 48–53. http://dx.doi.org/10.1016/j.peptides.2017.09.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Collie, N. L., J. H. Walsh, H. C. Wong, et al. "Purification and sequence of rat oxyntomodulin." Proceedings of the National Academy of Sciences 91, no. 20 (1994): 9362–66. http://dx.doi.org/10.1073/pnas.91.20.9362.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Blache, P., A. Kervran, and D. Bataille. "Oxyntomodulin and glicentin: Brain-gut peptides." Regulatory Peptides 18, no. 5-6 (1987): 349. http://dx.doi.org/10.1016/0167-0115(87)90207-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Alexiadou, Kleopatra, Joyceline Cuenco, James Howard, et al. "Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study." BMJ Open Diabetes Research & Care 8, no. 1 (2020): e001076. http://dx.doi.org/10.1136/bmjdrc-2019-001076.

Full text

Abstract:

IntroductionHyperglucagonemia is a key pathophysiological driver of type 2 diabetes. Although Roux-en-Y gastric bypass (RYGB) is a highly effective treatment for diabetes, it is presently unclear how surgery alters glucagon physiology. The aim of this study was to characterize the behavior of proglucagon-derived peptide (glucagon, glucagon-like peptide-1 (GLP-1), oxyntomodulin, glicentin) secretion after RYGB surgery.Research design and methodsProspective study of 19 patients with obesity and pre-diabetes/diabetes undergoing RYGB. We assessed the glucose, insulin, GLP-1, glucose-dependent insu

APA, Harvard, Vancouver, ISO, and other styles

19

Collie, NL, Z. Zhu, S. Jordan, and JR Reeve. "Oxyntomodulin stimulates intestinal glucose uptake in rats." Gastroenterology 112, no. 6 (1997): 1961–70. http://dx.doi.org/10.1053/gast.1997.v112.pm9178688.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lofthouse, Marie. "Oxyntomodulin—a novel treatment for human obesity." Nature Clinical Practice Endocrinology & Metabolism 1, no. 1 (2005): 9. http://dx.doi.org/10.1038/ncpendmet0009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Santoprete, Alessia, Elena Capitò, Paul E. Carrington, et al. "DPP-IV-resistant, long-acting oxyntomodulin derivatives." Journal of Peptide Science 17, no. 4 (2011): 270–80. http://dx.doi.org/10.1002/psc.1328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Dakin, C. L., I. Gunn, C. J. Small, et al. "Oxyntomodulin Inhibits Food Intake in the Rat." Endocrinology 142, no. 10 (2001): 4244–50. http://dx.doi.org/10.1210/endo.142.10.8430.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Muppidi, Avinash, Huafei Zou, Peng Yu Yang, et al. "Design of Potent and Proteolytically Stable Oxyntomodulin Analogs." ACS Chemical Biology 11, no. 2 (2016): 324–28. http://dx.doi.org/10.1021/acschembio.5b00787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

ThanThan, S., Y. Asada, T. Saito, et al. "Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle." Domestic Animal Endocrinology 44, no. 2 (2013): 70–80. http://dx.doi.org/10.1016/j.domaniend.2012.09.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Shah, Aesha, William C. Dodson, Penny M. Kris-Etherton, et al. "Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS." Journal of Clinical Endocrinology & Metabolism 106, no. 1 (2020): 108–19. http://dx.doi.org/10.1210/clinem/dgaa682.

Full text

Abstract:

Abstract Objective To examine the effects of common treatments for polycystic ovary syndrome (PCOS) on a panel of hormones (reproductive/metabolic). Design Secondary analysis of blood from a randomized controlled trial of three 16-week preconception interventions designed to improve PCOS-related abnormalities: continuous oral contraceptive pills (OCPs, N = 34 subjects), intensive lifestyle modification (Lifestyle, N = 31), or a combination of both (Combined, N = 29). Materials and Methods Post-treatment levels of activin A and B, inhibin B, and follistatin (FST), as well as Insulin-like growth

APA, Harvard, Vancouver, ISO, and other styles

26

Pollock, H. G., J. R. Kimmel, K. E. Ebner, et al. "Isolation of alligator gar (Lepisosteus spatula) glucagon, oxyntomodulin, and glucagon-like peptide: Amino acid sequences of oxyntomodulin and glucagon-like peptide." General and Comparative Endocrinology 69, no. 1 (1988): 133–40. http://dx.doi.org/10.1016/0016-6480(88)90062-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Scott, R., J. Minnion, T. Tan, and S. R. Bloom. "Oxyntomodulin analogue increases energy expenditure via the glucagon receptor." Peptides 104 (June 2018): 70–77. http://dx.doi.org/10.1016/j.peptides.2018.04.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Cohen, Mark A., Sandra M. Ellis, Carel W. Le Roux, et al. "Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans." Journal of Clinical Endocrinology & Metabolism 88, no. 10 (2003): 4696–701. http://dx.doi.org/10.1210/jc.2003-030421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

BLACHE, P., A. KERVRAN, and D. BATAILLE. "Oxyntomodulin and Glicentin: Brain-Gut Peptides in the Rat*." Endocrinology 123, no. 6 (1988): 2782–87. http://dx.doi.org/10.1210/endo-123-6-2782.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Audousset-Puech, M. P., M. Dufour, A. Kervran, et al. "Solid-phase peptide synthesis of human(Nle-27)-oxyntomodulin." FEBS Letters 200, no. 1 (1986): 181–85. http://dx.doi.org/10.1016/0014-5793(86)80535-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Fischer, Kirk D., Savita Dhanvantari, Daniel J. Drucker, and Patricia L. Brubaker. "Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats." American Journal of Physiology-Endocrinology and Metabolism 273, no. 4 (1997): E815—E820. http://dx.doi.org/10.1152/ajpendo.1997.273.4.e815.

Full text

Abstract:

Glucagon-like peptide 2 (GLP-2) has recently been identified as a novel intestinal growth factor. Because experimental diabetes is associated with bowel growth, we examined the relationship between GLP-2 and intestinal growth in rats made diabetic by streptozotocin (STZ) injection and treated with or without insulin for 3 wk. Ileal concentrations of the intestinal proglucagon-derived peptides, i.e., glicentin + oxyntomodulin, and GLPs 1 and 2, were increased by 57 ± 20% above those of controls in untreated STZ diabetes ( P < 0.05–0.001). Similar increases in plasma concentrations of glicent

APA, Harvard, Vancouver, ISO, and other styles

32

Du, Xiaobing, Jennifer R. Kosinski, Julie Lao, et al. "Differential effects of oxyntomodulin and GLP-1 on glucose metabolism." American Journal of Physiology-Endocrinology and Metabolism 303, no. 2 (2012): E265—E271. http://dx.doi.org/10.1152/ajpendo.00142.2012.

Full text

Abstract:

Glucagon-like peptide-1 (GLP-1) and oxyntomodulin (OXM) are peptide hormones secreted postprandially from the gut that stimulate insulin secretion in a glucose-dependent manner. OXM activates both the GLP-1 receptor (GLP1R) and the glucagon receptor (GCGR). It has been suggested that OXM acutely modulates glucose metabolism solely through GLP1R agonism. Because OXM activates the GLP1R with lower affinity than GLP-1, we generated a peptide analog (Q→E, OXMQ3E) that does not exhibit glucagon receptor agonist activity but retains the same affinity as OXM for GLP1R. We compared the effects of OXM

APA, Harvard, Vancouver, ISO, and other styles

33

Quellec, A. Le, A. Kervran, P. Blache, A. J. Ciurana, and D. Bataille. "Diurnal Profile of Oxyntomodulin-like Immunoreactivity in Duodenal Ulcer Patients." Scandinavian Journal of Gastroenterology 28, no. 9 (1993): 816–20. http://dx.doi.org/10.3109/00365529309104015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Tian, Yulin, Huafei Zou, Peng An, Zhihong Zhou, Weijun Shen, and Qing Lin. "Design of stapled oxyntomodulin analogs containing functionalized biphenyl cross-linkers." Tetrahedron 75, no. 2 (2019): 286–95. http://dx.doi.org/10.1016/j.tet.2018.11.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Le Quellec, A. "Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone." Journal of Clinical Endocrinology & Metabolism 74, no. 6 (1992): 1405–9. http://dx.doi.org/10.1210/jc.74.6.1405.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Anini, Youn??s, Claire Jarrousse, Jacques Chariot, et al. "Oxyntomodulin Inhibits Pancreatic Secretion Through the Nervous System in Rats." Pancreas 20, no. 4 (2000): 348–60. http://dx.doi.org/10.1097/00006676-200005000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Le Quellec, A., A. Kervran, P. Blache, A. J. Ciurana, and D. Bataille. "Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone." Journal of Clinical Endocrinology & Metabolism 74, no. 6 (1992): 1405–9. http://dx.doi.org/10.1210/jcem.74.6.1592887.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Druce, Maralyn R., Caroline J. Small, and Stephen R. Bloom. "Minireview: Gut Peptides Regulating Satiety." Endocrinology 145, no. 6 (2004): 2660–65. http://dx.doi.org/10.1210/en.2004-0089.

Full text

Abstract:

Abstract The gastrointestinal tract and the pancreas release hormones regulating satiety and body weight. Ghrelin stimulates appetite, and glucagon-like peptide-1, oxyntomodulin, peptide YY, cholecystokinin, and pancreatic polypeptide inhibit appetite. These gut hormones act to markedly alter food intake in humans and rodents. Obesity is the current major cause of premature death in the United Kingdom, killing almost 1000 people per week. Worldwide, its prevalence is accelerating. There is currently no effective answer to the pandemic of obesity, but replacement of the low levels of peptide YY

APA, Harvard, Vancouver, ISO, and other styles

39

Druce, Maralyn R., James S. Minnion, Benjamin C. T. Field, et al. "Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs." Endocrinology 150, no. 4 (2008): 1712–21. http://dx.doi.org/10.1210/en.2008-0828.

Full text

Abstract:

Oxyntomodulin (Oxm) is an intestinal peptide that inhibits food intake and body weight in rodents and humans. These studies used peptide analogs to study aspects of structure and function of Oxm, and the sensitivity of parts of the Oxm sequence to degradation. Analogs of Oxm were synthesized and studied using receptor binding and degradation studies in vitro. Their effects on food intake and conditioned taste avoidance were measured in vivo in rodents. Oxm breakdown by the enzyme dipeptidyl peptidase IV (DPPIV) was demonstrated in vitro and in vivo. In vitro degradation was reduced and in vivo

APA, Harvard, Vancouver, ISO, and other styles

40

Dakin, Catherine L., Caroline J. Small, Rachel L. Batterham, et al. "Peripheral Oxyntomodulin Reduces Food Intake and Body Weight Gain in Rats." Endocrinology 145, no. 6 (2004): 2687–95. http://dx.doi.org/10.1210/en.2003-1338.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Parlevliet, Edwin T., Annemieke C. Heijboer, Janny P. Schröder-van der Elst, et al. "Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet." American Journal of Physiology-Endocrinology and Metabolism 294, no. 1 (2008): E142—E147. http://dx.doi.org/10.1152/ajpendo.00576.2007.

Full text

Abstract:

We evaluated the acute effects of OXM on glucose metabolism in diet-induced insulin-resistant male C57Bl/6 mice. To determine the effects on glucose tolerance, mice were intraperitoneally injected with OXM (0.75, 2.5, or 7.5 nmol) or vehicle prior to an ip glucose tolerance test. OXM (0.75 nmol/h) or vehicle was infused during a hyperinsulinemic euglycemic clamp to quantify insulin action on glucose production and disposal. OXM dose-dependently improved glucose tolerance as estimated by AUC for glucose (OXM: 7.5 nmol, 1,564 ± 460, P < 0.01; 2.5 nmol, 1,828 ± 684, P < 0.01; 0.75 nmol, 2,3

APA, Harvard, Vancouver, ISO, and other styles

42

Tani, T., A. Le Quellec, C. Jarrousse, et al. "Oxyntomodulin and related peptides control somatostatin secretion in RIN T3 cells." Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1095, no. 3 (1991): 249–54. http://dx.doi.org/10.1016/0167-4889(91)90107-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

ThanThan, S., Y. Asada, T. Saito, et al. "Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle." Domestic Animal Endocrinology 59 (April 2017): 30–36. http://dx.doi.org/10.1016/j.domaniend.2016.10.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Zhang, Faming, Pengyun Li, Tanya Rogers, David Smiley, Richard DiMarchi, and Richard D DiMarchi. "Crystallization and Preliminary X-Ray Analysis of Anti-Obesity Peptide Hormone Oxyntomodulin." Protein & Peptide Letters 15, no. 2 (2008): 232–34. http://dx.doi.org/10.2174/092986608783489643.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Liu, Y.-L., H. E. Ford, M. R. Druce, et al. "Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents." International Journal of Obesity 34, no. 12 (2010): 1715–25. http://dx.doi.org/10.1038/ijo.2010.110.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Wynne, Katie, and Stephen R. Bloom. "The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control." Nature Clinical Practice Endocrinology & Metabolism 2, no. 11 (2006): 612–20. http://dx.doi.org/10.1038/ncpendmet0318.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Le Quellec, Alain, Marjorie Clapié, Pierre Callamand, et al. "Circulating Oxyntomodulin-like Immunoreactivity in Healthy Children and Children with Celiac Disease." Journal of Pediatric Gastroenterology & Nutrition 27, no. 5 (1998): 513–18. http://dx.doi.org/10.1097/00005176-199811000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Ma, Tao, Su Huo, Bing Xu, et al. "A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice." European Journal of Medicinal Chemistry 203 (October 2020): 112496. http://dx.doi.org/10.1016/j.ejmech.2020.112496.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

RODIER, G., R. MAGOUS, T. MOCHIZUKI, J. P. BALI, D. BATAILLE, and C. JARROUSSE. "A Target Cell to Oxyntomodulin and Glicentin: The Antral Smooth Muscle Cell." Annals of the New York Academy of Sciences 865, no. 1 VIP, PACAP, A (1998): 458–62. http://dx.doi.org/10.1111/j.1749-6632.1998.tb11215.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Wang, Li, Jin Zhao, Chang‐Tu Wang та ін. "D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice". CNS Neuroscience & Therapeutics 26, № 3 (2019): 343–54. http://dx.doi.org/10.1111/cns.13211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!